WHAT IS CANNABICITRAN (CRM)?
Cannabicitran (CBT) is one of the latest discoveries from the cannabis plant research. Although CBT is very similar to some other cannabinoid compounds, researchers are yet to categorize or specifically point out what family or compound bloc CBT belongs to. The cannabis plant has many benefits to the human world that we are yet to discover and therapeutic advantages we still don’t know.
The earliest record or mention of cannabicitran (CBT) was in 2012. The compound is said to be isolated from the Lebanese hashish, a Lebanese variant of the cannabis plant. This particular component is also said to be similar to the synthetic citrylidene-cannabis. Researchers were able to successfully isolate CBT even though it exists in minute quantities and sometimes isn’t even available in some cannabis plant. The work of scientists like Robert Cahn, R. K. Razdan, and some others have been of notable importance in these discoveries.
Being a phytocannabinoids, CBT occurs naturally in the cannabis sativa plant. Its formulation consists of a unique feature that exists in its chemical structure. It doesn’t have a hydrogen bond donor link. What this means is that the compound cannot donate hydrogen but rather accepts hydrogen only. With a hydrogen bond acceptor count of 2, it has a total rotatable bond count of 4. Research has also shown that the compound has 3 undefined atom stereocenter count. Aside from its chemical properties, there are no studies to reveal other information around the formulation of the CBT
The cannabis sativa plant, sometimes called marijuana, is a plant that requires more dedicated time for research to unlock its multiple features. The plant promises a future that sees the advance of research into curing ailments like cancer, schizophrenia, insomnia, and other pervasive conditions proving difficult for doctors to find a cure. We know that CBF will have its functions and merits even if we can’t say them for a fact today.
HOW DOES CRM WORK?
There is no clinical trial to know how this compound acts with the human body receptors. There is no test to indicate if it has psychoactive tendencies. We don’t know if it acts as a receptor blockage agent.
There are a couple of reasons for this lack of professional knowledge. For one, the ongoing tussle of marijuana usage in the global sphere is a worrying risk to stakeholders. The shortage of funds and scientific capital is another explanation. Scientists need funds to advance their cannabinoid research. However, they will not move ahead without the right legal measures and guidelines.
POSSIBLE THERAPEUTIC BENEFITS
We hope that scientists can tell us, with further research, what therapeutic advantage this compound has and whether it is psychoactive or not, and if it is an anti-agent. The lack of understanding of CBT functions translates to being ignorant of its therapeutic advantages. More clinical trials, studies, and research are important. The potential of this compound is as promising as that of the hemp plant as a whole.
- Its chemical formula is C21H30O2.
- CBT has a molar mass of 314.5 g/mol.
- Its IUPAC name is (6AR,9R,10AS)-6,6,9-Trimethyl-3-pentyl-6A,7,8,9,10,10A-hexahydro-6H-1,9-epoxybenzo[C]chromene.
- CBT annotation is similar to delta8-THC, Exo-Tetrahydrocannabinol, 9-Hydroxyhexahydrocannabinol, and Hexahydrocannabinol.
PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 59444393, Cannabicitran.
Iwata N, Kitanaka S. New cannabinoid-like chromane and chromene derivatives from Rhododendron anthopogonoides. Chem Pharm Bull (Tokyo). 2011;59(11):1409-12. doi: 10.1248/cpb.59.1409. PMID: 22041081.
Cayman Chemical: https://www.caymanchem.com/product/21295/cannabicitran-(crm)